Registration for Vision UK 2013 conference now open

Article

Registration for the fifth VISION 2020 UK Annual Vision Strategy is now open.

Registration for the fifth VISION 2020 UK Annual Vision Strategy is now open.

The conference will commence on Tuesday 11 June at the Queen Elizabeth II Conference Centre, London, UK. The main theme will be 'Progress through partnership' and will cover the launch of the refreshed UK Vision Strategy.

A series of workshops will be available for delegates, during which they will have the opportunity to contribute to implementation plans for the new strategy and hear opinions from public health experts in eyecare sectors.

Anna Lightstone, Programme Director, UK Vision Strategy and Interim Chief Operations, commented, "It is an exciting time as we launch the refreshed UK Vision Strategy and the conference will provide an excellent opportunity for those in the eye health, public health and sight loss sectors to plan how to successfully implement this over the next five years."

For those interested in sponsorship and exhibitor opportunities please ukvisionstrategy@rnib.org.uk the UK Vision Strategy team.

Please click here to book your place at the VISION 2020 2013 conference.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.